A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab

Protocol
11-166
Full Title
A Phase II Study of Afatinib in Patients with Advanced HER2-positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Phase
II
Purpose

Cancers of at the junction of the esophagus and stomach (esophagogastric cancers) that produce high levels of a protein called HER2 may be treated with trastuzumab, a drug that targets this protein. However, in some patients, the cancer continues growing despite trastuzumab therapy.

The goal of this study is to evaluate the safety and effectiveness of an investigational drug called afatanib (also called BIBW 2992), which also targets HER2, in patients with metastatic esophagogastric cancer that has continued to grow despite trastuzumab treatment. Afatinib is a pill that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have HER2-positive metastatic esophagogastric cancer that has continued to grow despite trastuzumab treatment.
  • At least 2 weeks must have passed since completion of prior therapy (trastuzumab or lapatinib) and entry into the study.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Yelena Janjigian at 646-888-4186.

Disease(s)
Upper Gastrointestinal: Esophageal Cancer
Upper Gastrointestinal: Gastric Cancer
Locations
Related Diseases